Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.5
5.1
Journals
Cells
Special Issues
Pathogenesis and Novel Therapies in Epithelial Cancers
share announcement

Pathogenesis and Novel Therapies in Epithelial Cancers

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 550

Special Issue Editors

Dr. Jung Wook Park

E-Mail Website
Guest Editor
Pathology, Clinical Science Departments & Cell Biology, Basic Science Departments, Duke University School of Medicine, Durham, NC, USA
Interests: functional genomics; prostate cancer; lung cancer; small-cell cancer; neuroendocrine cancer; genetically engineered disease model; transcriptome; epigenetics
Dr. Sanjeevram Dhandapani

E-Mail Website
Guest Editor
Pathology, Clinical Science Departments & Cell Biology, Basic Science Departments, Duke University School of Medicine, Durham, NC, USA
Interests: oncology; inflammation-immune; nanotechnology; biomaterials and multi-omics

Special Issue Information

Dear Colleagues, 

Cancers can develop in various epithelial tissues. The most common types of epithelial cancers are breast cancer, prostate cancer, lung cancer, colorectal cancer, and skin cancer. Despite recent advancements in therapeutic strategies, such as targeted therapy, antibody–drug conjugates, CAR-T immunotherapy, nanoparticle-based drug delivery, and personalized medicine, these cancers remain life-threatening. Therefore, addressing how human epithelial cancers are initiated, developed, and differentiated, and the molecular factors behind them, can allow us to identify molecular vulnerabilities and utilize advanced therapeutic strategies to treat cancer patients efficiently. This can provide new insights into the genetic alterations, epigenetic mechanisms, metabolic changes, and immune system factors that contribute to cancer initiation, development, and progression. This Special Issue will highlight recent advancements and future directions in epithelial cancer research. We invite the submission of original articles and reviews on molecular mechanisms, diagnostics, therapeutic advances, and translational research, combining basic research with clinical applications.

Dr. Jung Wook Park
Dr. Sanjeevram Dhandapani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transformation
  • malignant
  • oncogene
  • tumor suppressor
  • molecular mechanisms
  • epigenetic
  • metabolic
  • immune
  • biomarkers
  • personalized medicine
  • primary cells
  • small-molecule inhibitor

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 4805 KiB  
Article
A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance—A Role for Nicotinamide N-Methyltransferase
by Jessica A. Wright, Stephanie D. White, Gavin Frame, Ana Bosiljkov, Shahbaz Khan, Roni Haas, Qian Yang, Minzhi Sheng, Xiaoyong Huang, Geoff S. Higgins, Ian Mills, Michelle R. Downes, Danny Vesprini, Hans T. Chung, Robert A. Screaton, Hon S. Leong, Paul C. Boutros, Thomas Kislinger and Stanley K. Liu
Cells 2025, 14(11), 819; https://doi.org/10.3390/cells14110819 - 31 May 2025
Viewed by 355
Abstract
Prostate cancer cell lines are particularly clinically homogenous, mostly representing metastatic states rather than localized disease. While there has been significant work in the development of additional models, few have been created without oncogenic transformation. We derived a primary prostate cancer cell line [...] Read more.
Prostate cancer cell lines are particularly clinically homogenous, mostly representing metastatic states rather than localized disease. While there has been significant work in the development of additional models, few have been created without oncogenic transformation. We derived a primary prostate cancer cell line from a patient with localized Gleason 7 prostate cancer—designated CaB34—which spontaneously immortalized. We leveraged CaB34 to generate a paired radioresistant subline, CaB34-CF, using a clinically relevant fractionated radiotherapy schedule. These two paired cell lines were investigated extensively to determine their molecular characteristics and therapy responses. Both CaB34 and CaB34-CF express prostate-specific markers, including KRT18, NKX3.1, and AMACR. Multi-omic analyses using RNAseq and shotgun proteomics identified NNMT as the most significantly dysregulated component in CaB34-CF. A bioinformatic analysis determined that NNMT was more abundant within prostate tumors compared to benign prostate, suggesting a role in tumor progression. Knockdown studies of NNMT demonstrated significant radiosensitization of CaB34-CF cells, which was largely a result of increased radiation-induced cellular senescence. Growth as 3D organoids was significantly higher in the CaB34-CF line, and demonstrated a less structured pattern of expression of cytokeratin markers. Radiosensitization with NNMT siRNA was recapitulated in a 3D organoid clonogenic assay in CaB34-CF cells. Our research provides a paired primary model of treatment-naïve and radioresistant disease to address mechanisms of therapy resistance, while expanding the repertoire of localized prostate cancer cell lines for the research community. In addition, our findings present NNMT as a potential therapeutic target for sensitization of radioresistant disease. Full article
(This article belongs to the Special Issue Pathogenesis and Novel Therapies in Epithelial Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop